Phase XIII, group 3 - 01.09.2019 - 30.08.2022

Ca.-No 188

The role of CXCL10 in the immune regulation of melanoma and glioma

Israeli Partner: Nathan Karin, Technion
German Partner: Michael Platten, DKFZ

Publications

Ca.-No 189

Exploring the immunogenicity of DNA damage repair deficient pancreatic ductal adenocarcinoma (DDR-deficient PDA)

Israeli Partner: Talia Golan, Sheba Medical Center
German Partner: Rienk Offringa, DKFZ

Ca.-No 190

Exploiting the Achilles heel of hyperactivated mTORC1 for tumor therapy

Israeli Partner: Boaz Tirosh, Hebrew University
German Partner: Wilhelm Palm, DKFZ

Ca.-No 191

Dissecting the epigenetic landscape of cancer associated fibroblasts

Israeli Partner: Ruth Scherz-Shouval, Weizmann Institute
German Partner: Christoph Plass, DKFZ

Ca.-No 192

Improving cancer immunotherapy by novel nanotechnologies enabling cell type-specific drug delivery

Israeli Partner: Yosi Shamay, Technion
German Partner: Darjus Tschaharganeh, DKFZ

Publications

No publications available.

Ca.-No 193

Discovering and exploiting the role of amino acids metabolism as safeguard mechanisms from ionizing radiation-induced redox stress and as novel targets for radiosensitization therapies

Israeli Partner: Eyal Gottlieb, Technion
German Partner: Christiane Opitz, DKFZ

Publications

No publications available.

Formular

Formulardaten werden geladen ...